Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Proteasome inhibitors].

Kiyohiko Hatake1, Yuko Mishima, Yasuhito Terui

  • 1Department of Chemotherapy, Japanese Foundation for Cancer Research Hospital, 1-37-1 Kami-ikebukuro, Toshima-ku, Tokyo 170-8455, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

International journal of clinical oncology·2026
Same author

Factors associated with aggregate formation in cold-stored platelets.

Vox sanguinis·2026
Same author

Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Cancers·2026
Same author

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Leukemia·2026
Same author

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Cureus·2026
Same author

Bilateral orbital masses caused by IgG4-expressing MALT lymphoma in the right side and IgG4-related ophthalmic disease in the left side: A case report.

Modern rheumatology case reports·2026
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Bortezomib is a proteasome inhibitor effective for multiple myeloma and other cancers. Medical oncologists should monitor for adverse effects like hypotension, especially with overdose.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Bortezomib, a proteasome inhibitor, is approved for second-line multiple myeloma treatment in the US.
  • Clinical trials for bortezomib in multiple myeloma are ongoing in Japan.

Purpose:

  • To review the efficacy and mechanism of bortezomib in various cancers.
  • To analyze the mechanisms of bortezomib resistance.
  • To highlight potential adverse effects and necessary precautions.

Summary:

  • Bortezomib demonstrates efficacy in multiple myeloma, non-Hodgkin's lymphoma, and non-small cell lung cancer.
  • Proposed mechanism involves inhibition of NF-kappaB via IkappaB alpha.
  • Noted ineffectiveness in colorectal cancer and chronic lymphocytic leukemia.
  • Drug resistance mechanisms have been elucidated.

Related Experiment Videos

  • Adverse effects, including hypotension with overdose, require medical caution.

    • Impact:

    • Provides a comprehensive overview of bortezomib's therapeutic applications and limitations.
    • Emphasizes the importance of careful patient monitoring and dose management.
    • Informs clinical decision-making for oncologists and hematologists regarding bortezomib use.